The management of acute mywardial infarction has been evolving rapidly since 1980. The results of experimental and clinical studies have caused B growing consensus that reperfusion ofan occluded coronary artcry. performed in the first few hours of evolving acute myocardial infarction. often reduces early monality and reduces infarct size. For many teaeons. the use of thrombolytic therapy in patients with acute myocardial infarction has altered the way in which we evaluate and care for these patients. It is the purpose of this editorial to recommend changer in the mutine evaluation and care of patients with suspected acute myocardial infarction to provide for the safe and effective use of this new therapy.
Current status of thmmbdytic therapy. Studies using rtrwtokinase have Dmvided mat of our current clinical experience, although recombinant tissue-type plasminogcn activator @t-PA). a relatively fibrin-specific agent with a superior coronary recanalization rate, is under intensive investigation and has recently been made available for general use (I). Several randomized trials (2-4) have reported both the efficacy and benefit associated with intracoronary streptokinase. The importance of these early findings is not inconsequential: however, the inherent delay in initiating therapy with intracomnary treatment makes this appmach impractical for mat clinical situations. Intravenous admtnirtration obviates this problem. Recently, the results of two large intravenous thmmbolytic therapy trials fmm Europe have been reported (5-8). The GISSI (Gntppo Itaaliano per lo Studio della Streptochittaai nell'lnfarto) study (51, a large trial enrolling 11,806 patients, demonstrated a highly significant 18% reduction in 21 day mortality overall among patients treated with streptokinase within 12 h of the onset of chest pain. Mortality was reduced by 23% it. those treated within 3 hand by an astonishing 47% in those treated within I h. This benefit from therapy has recently been demonstrated to be sustained for at least I year (6). The ISAM (Intravenous Streptokinase in Acute Myocardial Infarction) trial (7) in Germany enmlkd 1,741 relatively low risk patients: it demonstrated a 12% reduction overall in 21 day htortality and a 20% reduction in those patients treated with streptakinase within 3 h of the onset of symptoms; however, these differences were not statistically significant. Most recently, the second international study of infarct survival (ISIS-2 trial) (9) reported a 33% reduction in martality (from about 12% to 8%) in the nearly 4,tXtO patients randomized to intravenous streptokinase within 4 h of the onset of symptoms as compared with control patients. It seems clear from these studies, as well as other abservatians, that patients with attterior myocardial infarction henefit nwst from coronary rawfusion. No study mtblished to date has been sudicienily l&e to demonstrateareduction in mortality in patients with inferior myocardial infarction.
Thrombolytic therapy plus attgioplssty. coronary reperfusion therapy will benefit as many patients as II). possible. The program must take into account the local To achieve the beneficial results of thrombolytic therapy, geography and distribution of hospital facilities and recoga well organized and efficient community emergency care niLe the need for transfer of a well defined subset of acutely rystem is required. Without such a system, any attempt to ill patients fmm less specialized hospitals to those with introduce a oroeram of earlv thrombolvtic theraw will be aw.ior~rao~.,c and sureical facilities. There need to be willineffective and may be uns&cessful o; result in'&reased risk for the p&x! or both.
Risks of tbmmbotytte therapy. The results of all these trials are encouraging, but should not be construed as evidence that such treatment should be given to all patients with an acute coronary syndrome. The use of thrombolytic therapy carries with it the risk of serious and occasionally fatal bleeding and its effect on reducing mortality in patients. other than the early treatment of those with anterior infarction. has not been established. Cardiac catheterization performed. in conjunction with the administration ofthmmbolytic agents results in a high incidence of bematoma at the arterial puncture site and ereatlv increases the need for blood &sfusion. The mod se&us complication is intracranial bleeding. In the GISSI trial, without the use of routine heparin, the incidence rate of stroke wasO.Z%: in the ISAM trial the overall incidence rate was 0.46%. In the TIM1 trial, with intravenous n-PA. the incidence rate of stroke has beenl.6%atadoseof150mggivenover6hand0.6%atl00 mggivenaverd h (12). Clearly, patients ofadvanced ageand those with a history of stroke, transient cerebral ischemia, severe hypertension. long-standing diabetes or other conditions possibly influencing the cerebral vasculature have an increased likelihood of intracerebral hemorrhage with the use of thrombolytic and associated heparin therapy.
In view of these introductow remarks. it is evident that m&& hod encou&ement by the medical communiry for the transport of high risk patients directly to nearby facilities that are best able to provide specialized care. This is an tmpotiaor divergence from the past when all such patients were routinely admitted to the closest tospitd.
Initial management of acute mycardii bSarrtton in the enwgeney department. Perhaps the tu'o greatest impedimentr to rapid reperfosion therapy are the patient's misinterpretation or denial of symptoms that prevents him or her from seeki& help and the delay from hospital admission to mmation of treatmcrd. Several processes often occur in the emergency department that serve to delay definitive care.
These include waiting for the results of routine blocd tests.
sending the patient for X-ray examination and extensive consultation with other physicians, including the patient's practitioner or cardiologist. or both. Couple these events witP the often slow, methodical delivery of medications fmm the pharmacy. and transporting the patient to the coronary care unh lhere reevaluation by a new medical team occws before initiating therapy. and delays of 1.5 to 2 h become common. In the past, emphasis has been on the accurate diagnosis of acute myocvdial infarction (for example, ex- Futuredevelopmenb. lfthrombolytic thempy is to have a tltese patients. The objective of this team is to expeditiously significant impact on acute and postinfarction mortality and identify those patients who are most likely to benefit from morbidity, it must he effected early and be widely applicable. rewfuiion therapy. Patients with chest pain are to be Given Ihe constraints of time and cost, it is neither epproscreened using a short history, limited physical examination and I2 lead ECL The patient with chest pain is then classified into one of four categories: II suspected acute myocardiel infarction with ST segment elevation, 2) possible infarction, 3) chest pain of uncertain origin and 4) nn evidence of infarction. This process of initial evaluation and triage should be accomplished within I5 to 20 min of the patient's arrival at the hospital. In cases of suspated acute myocardial infarction. an additional history is required to identify contraindicaiions for thmmbolytic therapy.
Treatment protoeoi. A uniform protocol should he established for the management of various types of patient8 with acute myocardial infarction so that treatment can be initiated without delay. A well established pmtocot will prevent confusion and reduce the need for timesonsuming consultation hefore the initiation of therepy, In mmt instances, the decision to administer intlavenous;hrombolytic therapy and its institution should be caroled out in the emergency department. Because serious complications can occur, informed consent should be obtained. If a cardiac catheterization and surgical program are available in the hospital. the dditional options of early coronary angiogaphy followed by angioplasty or revaacularization w&cry need to be considered in some high risk patients, including t&e in cardiogenic shock and those with contraindications to lhrombolytic theraw. After thrombolytic therapy is initiated, hep&nimt& is often recommended to reduce the likelihood of coronary reocclusion.
The manogemenr of venrricular rochycardia or jbrillalion. or both. before, during and after rhrombolytic therapy needs IO bc emphasized. Many patients who have undergone closed chest massage and direct cwent cardioversion sustain significant chest trauma that constitutes a relative contraindication to thrombolytic treatment. In addition, the use priate nor practical to rely on a system of care that would tmnsport all petients with myocerdial infarction to regiunal centers before reperfusion therapy is initiated. The availability of intravenously administered drugs such as ntreptokinase. urokinase and tissue plasminogen activator makes effective repetfusion tbempy appropriate in any hospital with an adequately trained 8taiT. There are several areas that can be addressed to reduce delay from the onset of symptoms to initiating treatment. In the pre-hospital phase, the routine use of a fully portable 12 Iced ECG for diagnosing acute myocardial injury and the administration of intravenous or intramuscular thrombolytic therapy before transport to the hospital must be studied. This approach offers the opportunity of earlier reperfusion but increases the risk of misdiagnosis and misuse of this therapy, which may result in serious comptications. Because it is known that very early therapy is most effective, careful evaluation of pre-hospital thmmbolytic therapy is urgently needed.
The role of early cardiac carhererization and angioplasry needs ro be defined in pcltienrs wirh acure myocardial infarcrion. Although residual high grade stenosis is a cornman finding after thrombolytic therapy, questions yet to be answered include: should all or only certain types of corn--nary stenoses receive additional t&tment withangioplasty and when should such procedures be carried out? The management of patients whose thrombosed artery fails to reperfuse with intravenous thmmbolytic therapy also needs to be defined. At present it is difficult to identify those patients without angiography. Even if they are identified, those patients in most instances cannot undergo angioplasty quickly enough to salvage iscbemic myocardium.
of central intravenous lines placed during resuscitation also sion rheropy. The most challenging problem will be educatincreases the risk of serious hemorrhagic complications.
ing and modifying the behavior of patients through atxwopriTherefore. patients who have received cardio&monary .
ate public education programs that encourage early resuscitation are at increased risk and. in many instances, evaluation of patients who are at risk for acute myocardial should not receive thmmbolytic treatment. On the other infarction. Although organizations such as the American hand. patient8 who have had en aneventful direct current Heart Association have made major effmis in public educb conlioversion with no chest compression and who have only lion to reduce the time from onset of symptoms to the time peripheral intravenous lines in place are suitable for tbmmbolytic therapy. If ventricular fibrillation occurs in a patient when patients seek help. the denial of symptoms and delay in seeking care are still perhaps the greatest impediments to who has received thrombolytic therapy, as in all cases of early treatment. Our current understanding of the oathoohvcardiac arrest, electrical defibrillation should precede chest siology of tmnsmural infarction suggests bat tbe'"wi~d& compression if a defibrillator is immediately available. Beof opportunity" is narrow and that a I h reduction in the cause of the pe!ential of intratboracic bleeding. chest compression should only bz used aft-r defibrillation has failed to delay-from onset of symptoms to treatment can make a major impact in reducing the morbidity and mortality of produce M organized rhythm. myocardial infarction.
